Clinical Trial Detail

NCT ID NCT03717415
Title A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Deciphera Pharmaceuticals LLC
Indications

malignant pleural mesothelioma

ovarian cancer

Advanced Solid Tumor

breast cancer

peritoneal mesothelioma

Therapies

Carboplatin + Rebastinib

Age Groups: adult senior

No variant requirements are available.